# VISUAL II 👉🏼WHAT IS IT ? efficacy and safety in preventing flare-up in pharmacologically controlled noninfectious uveitis (10–35 mg prednisone and/or 1 IMT) 👉🏼 CONCLUSION The ADA group was less likely than the placebo group to have treatment failure the incidence of adverse and serious adverse events was similar between treatment groups.